NCT03881605View on ClinicalTrials.gov

MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or HER2+ MBC

NAActive, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 8, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Breast NeoplasmBrain MetastasesTriple Negative Breast CancerHER2-positive Breast Cancer
Interventions
DIAGNOSTIC_TEST

MRI screening

A standard contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain will be performed at baseline, 4 months, 8 months and 12 months.

Trial Locations (1)

M4N3M5

Sunnybrook Odette Cancer Centre, Toronto

All Listed Sponsors
collaborator

Harvard University

OTHER

lead

Sunnybrook Health Sciences Centre

OTHER

NCT03881605 - MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or HER2+ MBC | Biotech Hunter | Biotech Hunter